Article Title: ‘Most complete’ map of oral microbiome enables links to systemic disease
Publication Date: November 18, 2025
In a recent publication in Cell Host & Microbe dated November 12, 2025, scientists under the leadership of Lee In-suk at Yonsei University in South Korea have created the most comprehensive map of the oral microbiome available, boasting of over 72,000 genomes. This catalog is expected to act as a foundation for universal research in academia and facilitate the growth and application of ‘precision microbiome medicine’ within the biotech industry, according to direct statements by Lee to BioWorld.
This breakthrough has significant implications in terms of understanding and treating diseases. It constitutes a remarkable database that will enable the broader scientific community to explore links between the oral microbiome and systemic diseases. Having access to such data – over 72,000 genomes – has the potential to advance precision medicine, focusing on the use of precise microbial therapies aimed to correct disease conditions.
From a business perspective, the development has substantial ramifications, offering the industry an opportunity to develop targeted patient therapies. Pharmaceutical and biotech companies may stand to gain substantially from designing personalized microbiome-based therapeutic solutions, thereby offering potentially effective treatments that could transform patient outcomes. Companies may want to focus on exploring this recent development as an opportunity to leverage their microbiome-focused research and development efforts.
Investors should take note of biotech companies dedicated to studying the human microbiome to gain insights into patient health. There’s an encouraging potential for growth within companies that successfully harness this opportunity and translate this emerging science into safe and effective treatments. Lastly, this database signifies a shift in the landscape of medical research and potential therapeutic modalities, solidifying the role of microbiome-related research in the pursuit of precision medicine.
In closing, this recent advancement highlights the accelerated pace of innovation and collaboration in biotech. At Industry Informant, we aim to provide the latest industry shifts and insights, equipping key decision-makers with up-to-date, actionable intelligence.
